BioSpace News Archive

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2020. First Quarter 2020 and Recent Operating Highlights Revenue of $8.3 million for the first quarter of 2020; E-commerce sales to 24% of total net revenue, up from 15% for the first quarter of 2019; Launched upd

The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S. -- All six analyzed moderate-to-severe COVID-19 patients treated with opaganib under compassionate use in Israel were weaned from oxygen and discharged from the hospital -- Opaganib’s unique mechanism of action has both anti-inflammatory and anti-viral activities, targeting a critical host factor, minimizing potential development of resistance du

Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 5,000,000 of the Company’s ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced the closing of an underwritten public offering of 6,808,154 shares of its common stock at a public offering price of $39.00 per share.

BIOREM Inc. announced its results for the three and twelve-month periods ended December 31, 2019.

IntelGenx Corp., a leader in pharmaceutical films, announced that it will release its first quarter 2020 financial results after market close on May 14, 2020.

AbbVie, a research-based global biopharmaceutical company, announced that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.

For the first time, Americans will have access to at-home testing for COVID-19 through Vault Health, utilizing the first FDA EUA approved saliva test from RUCDR Infinite Biologics and Spectrum Solutions.

Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company’s operations.

Providers to benefit from free access to leading payer-provider collaboration platform through May